vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and DNA X, Inc. (SONM). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $16.2M, roughly 1.1× DNA X, Inc.). SCYNEXIS INC runs the higher net margin — 65.7% vs -29.3%, a 95.1% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 7.9%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 9.9%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
SCYX vs SONM — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $16.2M |
| Net Profit | $12.3M | $-4.8M |
| Gross Margin | — | 11.2% |
| Operating Margin | 56.3% | -24.5% |
| Net Margin | 65.7% | -29.3% |
| Revenue YoY | 1808.5% | 7.9% |
| Net Profit YoY | 376.5% | -89.2% |
| EPS (diluted) | $0.25 | $-4.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | — | ||
| Q3 25 | $334.0K | $16.2M | ||
| Q2 25 | $1.4M | $11.2M | ||
| Q1 25 | $257.0K | $16.7M | ||
| Q4 24 | $977.0K | $15.3M | ||
| Q3 24 | $660.0K | $15.0M | ||
| Q2 24 | $736.0K | $11.5M | ||
| Q1 24 | $1.4M | $9.1M |
| Q4 25 | $12.3M | — | ||
| Q3 25 | $-8.6M | $-4.8M | ||
| Q2 25 | $-6.9M | $-7.5M | ||
| Q1 25 | $-5.4M | $458.0K | ||
| Q4 24 | — | $-21.6M | ||
| Q3 24 | $-2.8M | $-2.5M | ||
| Q2 24 | $-14.5M | $-6.6M | ||
| Q1 24 | $411.0K | $-2.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | 11.2% | ||
| Q2 25 | — | 7.6% | ||
| Q1 25 | — | 50.0% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | — | 28.2% | ||
| Q2 24 | — | 25.8% | ||
| Q1 24 | — | 31.8% |
| Q4 25 | 56.3% | — | ||
| Q3 25 | -2516.5% | -24.5% | ||
| Q2 25 | -701.0% | -60.2% | ||
| Q1 25 | -3350.2% | 3.9% | ||
| Q4 24 | — | 55.3% | ||
| Q3 24 | -1563.6% | -15.8% | ||
| Q2 24 | -1255.0% | -56.2% | ||
| Q1 24 | -692.5% | -29.5% |
| Q4 25 | 65.7% | — | ||
| Q3 25 | -2572.2% | -29.3% | ||
| Q2 25 | -504.8% | -66.8% | ||
| Q1 25 | -2097.7% | 2.7% | ||
| Q4 24 | — | -141.6% | ||
| Q3 24 | -425.5% | -16.7% | ||
| Q2 24 | -1964.4% | -57.5% | ||
| Q1 24 | 29.9% | -31.9% |
| Q4 25 | $0.25 | — | ||
| Q3 25 | $-0.17 | $-4.83 | ||
| Q2 25 | $-0.14 | $-0.79 | ||
| Q1 25 | $-0.11 | $0.08 | ||
| Q4 24 | — | $-116.99 | ||
| Q3 24 | $-0.06 | $-9.32 | ||
| Q2 24 | $-0.30 | $-1.41 | ||
| Q1 24 | $0.01 | $-0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $2.1M |
| Total DebtLower is stronger | — | $5.1M |
| Stockholders' EquityBook value | $49.4M | $-701.0K |
| Total Assets | $59.0M | $40.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.0M | — | ||
| Q3 25 | $37.9M | $2.1M | ||
| Q2 25 | $44.8M | $2.0M | ||
| Q1 25 | $40.6M | $2.1M | ||
| Q4 24 | $59.3M | $5.3M | ||
| Q3 24 | $68.8M | $9.1M | ||
| Q2 24 | $73.0M | $9.6M | ||
| Q1 24 | $80.2M | $9.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $2.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $-701.0K | ||
| Q2 25 | $44.5M | $-1.3M | ||
| Q1 25 | $50.5M | $-1.1M | ||
| Q4 24 | $55.1M | $-5.7M | ||
| Q3 24 | $58.5M | $15.3M | ||
| Q2 24 | $60.4M | $17.5M | ||
| Q1 24 | $74.1M | $19.8M |
| Q4 25 | $59.0M | — | ||
| Q3 25 | $51.1M | $40.2M | ||
| Q2 25 | $60.7M | $36.1M | ||
| Q1 25 | $67.9M | $36.0M | ||
| Q4 24 | $90.6M | $39.7M | ||
| Q3 24 | $99.0M | $49.1M | ||
| Q2 24 | $107.8M | $45.9M | ||
| Q1 24 | $118.3M | $42.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | $-7.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | — | ||
| Q3 25 | $-8.7M | $-7.0M | ||
| Q2 25 | $-7.5M | $-4.9M | ||
| Q1 25 | $-7.5M | $-9.6M | ||
| Q4 24 | $-24.0M | $-4.5M | ||
| Q3 24 | $765.0K | $-417.0K | ||
| Q2 24 | $-10.9M | $-3.4M | ||
| Q1 24 | $-4.0M | $-168.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-4.5M | ||
| Q3 24 | — | $-554.0K | ||
| Q2 24 | — | $-3.4M | ||
| Q1 24 | — | $-198.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -29.6% | ||
| Q3 24 | — | -3.7% | ||
| Q2 24 | — | -29.8% | ||
| Q1 24 | — | -2.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | 1.50× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -20.97× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -9.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
SONM
Segment breakdown not available.
